Novartis’s $90 million Swiss factory to help solve cell therapy bottleneck

Swiss drugmaker Novartis’s new $90 million cell and gene therapy factory in northern Switzerland is on track to begin commercial production of treatments, including Kymriah for cancer and Zolgensma for spinal muscular atrophy, in 2020.

…read more

Source:: Reuters – Business News